YouSaid · the spoken record

Othman Laraki

lines on the record: 79
first: 2017-01-02
most recent: 2017-01-02
sittings or episodes: 1
sources: podcast

Every line below is reproduced as it was said and linked to the record it came from. Nothing here is summarised or generated. Directory · Search · Corrections

“Discounting everything else, this one person today is alive maybe wouldn't have been if we hadn't been doing our work. And so I think that is very, very different feeling. And I think it really changes the feeling of responsibility of what we're doing, as well as our mental math around why it's worthwhile. And that's been, I think, a huge factor in our ability to build a team like we did. I mean, we have one of the things that I feel most fortunate about means we've been able to attract to the company, which is an incredible group of people, some of the best people we've ever worked with through all these amazing companies. And these are people that could be, you know, Getting paid more, etc., etc. But like the, you know, we're all connected to this in a very personal way.”
2017-01-02 · Decoder with Nilay Patel · Recode Decode: Othman Laraki, CEO, Color · IDENTIFIED FROM THE TRANSCRIPT
“Not really a life goal that I'd imagine you have. Yeah, that would be a new one. But I think what's very different here is that you get sometimes an n of one that justifies, that makes your last year worthwhile, right? Like, you know, sometimes you'll get literally one person and you're like, wow,”
2017-01-02 · Decoder with Nilay Patel · Recode Decode: Othman Laraki, CEO, Color · IDENTIFIED FROM THE TRANSCRIPT
“Yeah, I mean, I think one of the big differences when you're dealing with something like Google or Twitter, et cetera, I mean, the number of people you're touching is in the hundreds or a billion people, et cetera. And so the magnitude of humanity is incredible.”
2017-01-02 · Decoder with Nilay Patel · Recode Decode: Othman Laraki, CEO, Color · IDENTIFIED FROM THE TRANSCRIPT
“In some ways, I mean, your genome is no different than your lipid, your glucose panel, right? And it just used to be much more expensive and all this scaffolding of rationalization has been built around why you should only look at it under these conditions. But in reality, it's just data. It's just information that we use a lot of other information. And here it's like all of a sudden now this information is accessible And you can use it to really impact people”
2017-01-02 · Decoder with Nilay Patel · Recode Decode: Othman Laraki, CEO, Color · IDENTIFIED FROM THE TRANSCRIPT
“When I look at our customer base, I mean, it is all over the US. I mean, it is, I mean, we literally get people who write into our support.”
2017-01-02 · Decoder with Nilay Patel · Recode Decode: Othman Laraki, CEO, Color · IDENTIFIED FROM THE TRANSCRIPT
“Well, no, I think those are still the economics around those are still positive. But my point more is that, for example, being able to get insight into your cancer risk has all of a sudden become Way, way worthwhile for the population”
2017-01-02 · Decoder with Nilay Patel · Recode Decode: Othman Laraki, CEO, Color · IDENTIFIED FROM THE TRANSCRIPT
“Yes and no. I mean, like if you look at, for example, if you compare to Pap Smears, right? So there are about 70 million PAP smears that are done in the US every year. The positive rate of PAP smears is literally, I think. You know, almost an order of magnitude lower than what you'd see with cancer at risk, but now all of a sudden it's the same cost, right? So people are willing to do these things. From an impact standpoint. So I think it's much more actually of a”
2017-01-02 · Decoder with Nilay Patel · Recode Decode: Othman Laraki, CEO, Color · IDENTIFIED FROM THE TRANSCRIPT
“Well, but that's where I think where we're going, where it's literally now economically feasible and profitable to enable every single person to get tested.”
2017-01-02 · Decoder with Nilay Patel · Recode Decode: Othman Laraki, CEO, Color · IDENTIFIED FROM THE TRANSCRIPT
“I think the thing that has almost always happened has been around technology being a way to democratize progress in a way that's scalable to everyone. And so, well, such as, for example, cancer testing, right? Like with what we're doing, literally today, 20 years after these discoveries have been made, only about 15% of people who have high risk of breast or ovarian cancer in the US know about it. Right. So why isn't it?”
2017-01-02 · Decoder with Nilay Patel · Recode Decode: Othman Laraki, CEO, Color · IDENTIFIED FROM THE TRANSCRIPT
“Everything they do. That's a really interesting question. I mean, I think in some ways, like if you look at the two extremes, right? There's one extreme, it's like, okay, for the people who can put infinite resources to do either good or crazy things, right? And do you give superpowers to kind of some people be living eternally or do et cetera? I think that's always been, I think, you know, like Mary Shelley is Frankenstein. That's that kind of that myth or kind of anxiety has always existed relative to humans and technology.”
2017-01-02 · Decoder with Nilay Patel · Recode Decode: Othman Laraki, CEO, Color · IDENTIFIED FROM THE TRANSCRIPT
“Right. That's one of them. And the other is what do we become as human beings? There's a whole push in Silicon Valley around. The singularity, the this, the that, the idea that we become computers, we just interviewed Elon Musk. He was talking about putting in the networks. So we can keep up with computers. There's all kinds of things like that. And I think healthcare is where it really intersects. And the fact that we can do this at such a high level and yet most people in this country have terrible health care across the world, have terrible health care. So how does that iterate?”
2017-01-02 · Decoder with Nilay Patel · Recode Decode: Othman Laraki, CEO, Color · IDENTIFIED FROM THE TRANSCRIPT
“The one thing that's likely to be relatively limited is our ability to input the data, to read it ourselves, like the bandwidth of human eyes or ears or whatever. And so I think what likely happens is that we just build more tools that enable us to Use a lot of data in a human actionable way. I mean, I think part of your question to those like. Okay, what happens with perfect information? Do we start making weird societal choices? Right, that's one of them. And the other is”
2017-01-02 · Decoder with Nilay Patel · Recode Decode: Othman Laraki, CEO, Color · IDENTIFIED FROM THE TRANSCRIPT
“And it sort of orders you around as a body. You know, it starts telling you things Where does that go to? How much information should you have all that information about yourself constantly? Is that a good thing? And where does it go? How much information will we be getting?”
2017-01-02 · Decoder with Nilay Patel · Recode Decode: Othman Laraki, CEO, Color · IDENTIFIED FROM THE TRANSCRIPT
“No, I'm a proponent of, I just had some Fitbit or one of them, or Nike was in here, and I was like, these are useless because they're not saying you ate that donut. Here's what happened. You need to get up.”
2017-01-02 · Decoder with Nilay Patel · Recode Decode: Othman Laraki, CEO, Color · IDENTIFIED FROM THE TRANSCRIPT
“Oh, no. And I think part of that is that feedback loop. And so I think being able to plug into, for example, glucose monitor, if you every time you pop a snicker's bar, you get a graph that you see that. No, I'm a proponent of”
2017-01-02 · Decoder with Nilay Patel · Recode Decode: Othman Laraki, CEO, Color · IDENTIFIED FROM THE TRANSCRIPT
“Right now, the things that are easiest to act on are things where the actionability is very coarse, like specific, right? Like when for cancer, people tend to really follow the guidelines because it's say, you know, you just need to go get screened once a year or you need to go choose to get a colonoscopy or whatnot, things that have historically been very difficult are things that are more habit modification. So it's like, okay, if you consume less sugar.”
2017-01-02 · Decoder with Nilay Patel · Recode Decode: Othman Laraki, CEO, Color · IDENTIFIED FROM THE TRANSCRIPT
“Yeah, exactly. Do everything. But I think what happens is, you know, at least, first of all, from an individual selfcare standpoint, all the choices that we can make around everyday life choices that can have a very big impact, right? And so at least giving people I think when people start having a lens into that, it becomes much easier to improve our choices. I think another thing that I think is going to be quite interesting is.”
2017-01-02 · Decoder with Nilay Patel · Recode Decode: Othman Laraki, CEO, Color · IDENTIFIED FROM THE TRANSCRIPT
“Yeah, I mean, the way I think about it is each one of us, we have a torrent of data in our bodies. We're generating a tremendous amount of data. And today we make use of almost none of that data until they”
2017-01-02 · Decoder with Nilay Patel · Recode Decode: Othman Laraki, CEO, Color · IDENTIFIED FROM THE TRANSCRIPT
“We're going to talk a little bit about the future. Do you think it's a good thing because there's a play called Twilight of the Golds, where they found out, I think this woman who had a gay brother found out their baby still to be born was going to be gay. And then considered getting rid of it. This was back in the 80s, AIDS issues and stuff like that. And it was really, I remember it being the questions about what you do when you have all this information, all this genetic information. Where does it go? How much? What are we going to get to if you're going out when you're in a business? It's going to be all about this, where you're going to be able to digitize yourself”
2017-01-02 · Decoder with Nilay Patel · Recode Decode: Othman Laraki, CEO, Color · IDENTIFIED FROM THE TRANSCRIPT
“There was an interesting thing I saw last night at the breakthrough prizes where someone who got hata, and I'm blanking on her name, but she had been part of the reason she got it was she was doing genetic testing on a certain gene that created a disease and then that you pass on to your kids. The person knew about it, and then they were able to bypass it for their kids. It was really fantastic. So, this guy had it. Manifested it, but his kids will never get it, which I thought was really interesting.”
2017-01-02 · Decoder with Nilay Patel · Recode Decode: Othman Laraki, CEO, Color · IDENTIFIED FROM THE TRANSCRIPT
“No. For this, at least for these genes currently, I mean, they're adult onset, which means that there's no actionability change until you're in your 20s anyway. So, you know, I think it'll be their choice for when”
2017-01-02 · Decoder with Nilay Patel · Recode Decode: Othman Laraki, CEO, Color · IDENTIFIED FROM THE TRANSCRIPT
“Did you know that before? Yeah, I have two young boys. But I knew about it beforehand. And for me, for example, increased risk for a few different cancers.”
2017-01-02 · Decoder with Nilay Patel · Recode Decode: Othman Laraki, CEO, Color · IDENTIFIED FROM THE TRANSCRIPT
“I mean, in general, I mean. If I saw 70, I'd freak out. Yeah, I mean, in general, with all these things, I mean, it's, you know, I mean, in my personal case, right? It was obviously not good news, but when you know about it, you're like, okay, well, it is what it is. But now that I know, here are the three things. So you have this gene.”
2017-01-02 · Decoder with Nilay Patel · Recode Decode: Othman Laraki, CEO, Color · IDENTIFIED FROM THE TRANSCRIPT
“Yeah, you know, so I mean, each person has different permutations and risks. There are certain cases where people have mutations in multiple genes. And you adjust the guideline. The guidelines adjust based on that. Right. And you don't”
2017-01-02 · Decoder with Nilay Patel · Recode Decode: Othman Laraki, CEO, Color · IDENTIFIED FROM THE TRANSCRIPT
“Oh, sure. Yeah, yeah So we've tried to reduce the, I mean, obviously, but we tried to reduce the friction there, for example, by making videos and really kind of making easier for them on the education front. That's also why we require.”
2017-01-02 · Decoder with Nilay Patel · Recode Decode: Othman Laraki, CEO, Color · IDENTIFIED FROM THE TRANSCRIPT
“Helpful. Yeah. Yeah. So, I mean, a big part of it is for people to be informed ahead of making that choice. So ensuring that people are making a very informed decision. Second is”
2017-01-02 · Decoder with Nilay Patel · Recode Decode: Othman Laraki, CEO, Color · IDENTIFIED FROM THE TRANSCRIPT
“Awareness, which you can get, or a lot of these things, if you can get them early, they're quite helpful. Do you ever worry about people finding these things out and freaking out, like having the freak out? Because I remember getting some of the genetic information from 23andMe and it was disturbing”
2017-01-02 · Decoder with Nilay Patel · Recode Decode: Othman Laraki, CEO, Color · IDENTIFIED FROM THE TRANSCRIPT
“But what you end up having is you end up with when people have this elevated risk is that when their doctors know about it, they can adjust their screening in a way that increases chances of catching awareness.”
2017-01-02 · Decoder with Nilay Patel · Recode Decode: Othman Laraki, CEO, Color · IDENTIFIED FROM THE TRANSCRIPT
“Doing blank or so for each one of these, there's either whether it's cancer risk or gene, there are national guidelines for what you do if you have a mutation in one of these. And so in some cases it is skin cancer. For skin cancer, it's like increased screening, obviously increasing vigilance around sun exposure, et cetera.”
2017-01-02 · Decoder with Nilay Patel · Recode Decode: Othman Laraki, CEO, Color · IDENTIFIED FROM THE TRANSCRIPT
“She's been a huge proponent of it. Screamed at me until I did it. But what was interesting is it was helpful. It was good because I was thinking, what could you do then? What action could you take? Yeah. If you had that or something else, same thing with breast cancer. But you don't give them advice then. You have this, now you need to stop doing blank or you”
2017-01-02 · Decoder with Nilay Patel · Recode Decode: Othman Laraki, CEO, Color · IDENTIFIED FROM THE TRANSCRIPT
“That's good. And the good thing about colonoscopy is in addition to, I guess, the enjoyment of some cases is that they're actually very effective when polyps are detected early. It could allow someone, for example, with an APC mutation to literally potentially add decades to their lives.”
2017-01-02 · Decoder with Nilay Patel · Recode Decode: Othman Laraki, CEO, Color · IDENTIFIED FROM THE TRANSCRIPT
“Is the population or what? Yeah, so we can use a concrete example. So, for example, there's a gene called APC, where if you have a mutation in it, you have an extremely high risk of colon cancer. The average population is about 3% colon cancer risk. If you have APC mutation, you literally go up to between 70 and 100% risk. So the likelihood of getting isronical. But if someone knows about it, while colonoscopies are not pleasant, they're very effective. I just had one.”
2017-01-02 · Decoder with Nilay Patel · Recode Decode: Othman Laraki, CEO, Color · IDENTIFIED FROM THE TRANSCRIPT
“Paying for it and paying for it, yes. So where it's the model is direct pay. So we don't go through insurance. People just make that choice with them and their doctors or with their employers and enables them to get access to information currently focused on cancer where some people have a very high risk of cancer and then there are well-established guidelines about what they can do about it once they find it.”
2017-01-02 · Decoder with Nilay Patel · Recode Decode: Othman Laraki, CEO, Color · IDENTIFIED FROM THE TRANSCRIPT
“And you pass their sniff test essentially. And so there are, I think, things there that I think allow companies, whether it's Silicon Valley or not, to be able to say, look, you know, what we do is real and it works and, you know, it's well established, et cetera. I think separately from that, there's the question of control of and how it changes the jobs of doctors. And I think with that, you'll see it's just a big distribution. I mean, there are doctors that when we started color three, four years ago were still on the side of increasing access is dangerous, et cetera. And by now, it's like there's so much data that shows how big of a cost it is for people to not have access that they've really kind of swung to the other side.”
2017-01-02 · Decoder with Nilay Patel · Recode Decode: Othman Laraki, CEO, Color · IDENTIFIED FROM THE TRANSCRIPT
“Peer driven group where there are what we call key opinion leaders where they're just well known scientists who tend to have strong opinions that are respected and hopefully in general for a good reason. So when you work with people that have that kind of credibility, it does enable you to establish that you had someone who really can go very deep with you”
2017-01-02 · Decoder with Nilay Patel · Recode Decode: Othman Laraki, CEO, Color · IDENTIFIED FROM THE TRANSCRIPT
“Attitude. I think maybe this maybe is worth separating two things. I think one is how do you establish that a product works And I think for that, actually, the medical system has some pretty reasonable standards when you criticize it, et cetera. But like, so there's the genes, there's also kind of how do you establish that a product works. So, you know, for example, one thing we've done is we've been very transparent with our data. And so when we validated our test, we validated against very well accepted tests, and we published that very openly. Right, which is important. And that kind of peer review nature of medicine, I think, is actually quite effective. Another aspect of that is medicine is a very”
2017-01-02 · Decoder with Nilay Patel · Recode Decode: Othman Laraki, CEO, Color · IDENTIFIED FROM THE TRANSCRIPT
“Had the efficacy that was promised. And so it's an interesting dichotomy between Silicon Valley and the medical community where they obviously would welcome more information at the same time. They would like the priest kind of attitude”
2017-01-02 · Decoder with Nilay Patel · Recode Decode: Othman Laraki, CEO, Color · IDENTIFIED FROM THE TRANSCRIPT
“Very important for kids. For my kids, et cetera. But there is this paternalistic system that you have to get through. Having been in it, it's literally, I'm a plague to doctors because I'm always like, you know, they'll give me some answer that's not correct. Or just, I listen to what they're saying. And I go, you don't know, do you? And they're like, they gave me some mumbo and I said, I speak English, you don't know. And they're like, and I go, you just say you don't know, and I'm good with that. And which is interesting is that a lot of this, and then you have something like Theranos where it comes true that maybe this is a, you know, maybe this isn't.”
2017-01-02 · Decoder with Nilay Patel · Recode Decode: Othman Laraki, CEO, Color · IDENTIFIED FROM THE TRANSCRIPT
“Whereas individuals, I think, are very aligned with. Know not missing those opportunities, like you know, for me, knowing that I'm a BRCA2 carrier is very important for my kids, et cetera.”
2017-01-02 · Decoder with Nilay Patel · Recode Decode: Othman Laraki, CEO, Color · IDENTIFIED FROM THE TRANSCRIPT
“Well, I think the system or the kind of, you know, in general, like when we talk about the quote unquote system is that it tends to be more punished for risk taking and less rewarded for missing opportunities. Yeah, exactly. And also, but it doesn't get punished for the missed opportunities.”
2017-01-02 · Decoder with Nilay Patel · Recode Decode: Othman Laraki, CEO, Color · IDENTIFIED FROM THE TRANSCRIPT
“Whereas, yeah, on paper, and with terrible handwriting that even the people who wrote it can't read it most times. And to a point now where Maybe some of the most important health data is being generated about you on your phone while you're walking, you know, your heart rate monitor like with continuous glucose monitors, now it's becoming easier and easier to track that. Your genome, for example, these are data sets now that people are in control of. And I think that will change the power dynamics.”
2017-01-02 · Decoder with Nilay Patel · Recode Decode: Othman Laraki, CEO, Color · IDENTIFIED FROM THE TRANSCRIPT
“But I think with regards to private information, I think the first big thing that's happening is that people now are starting to have more and more of the expectation that the data is theirs and that they get to decide in two ways. I think first of all, it's kind of like the, or I think one of the big changes is that we went from the majority of your health data being generated and kept in hospital records.”
2017-01-02 · Decoder with Nilay Patel · Recode Decode: Othman Laraki, CEO, Color · IDENTIFIED FROM THE TRANSCRIPT
“Why can't we? Yeah, it's a good question, actually. I think I was discussing this with someone recently where I think in, for example, if you take the internet, there's been a, I think it's an interesting example of how, for example, there's been a relatively high level of self-regulation. By internet companies and also by organizations that are kind of the privacy watchdogs that apply pressure to ensure companies are also self-policing.”
2017-01-02 · Decoder with Nilay Patel · Recode Decode: Othman Laraki, CEO, Color · IDENTIFIED FROM THE TRANSCRIPT
“Yeah, they'll gather more data from your car than your doctor will get if you go in for cancer treatment. Right, and that's incredible, right? Like, is that, you know, we have the ability to extract that data, to read that data from our bodies and to be able to use it at scale. And I think we are in that transition time where we need to, we're A building the software for that, but also adjusting the medical system is also adapting to the availability of this incredible new tool set.”
2017-01-02 · Decoder with Nilay Patel · Recode Decode: Othman Laraki, CEO, Color · IDENTIFIED FROM THE TRANSCRIPT
“Say jokingly, but it's real is that when you take your car in for an oil change, your mechanic will plug your car into a computer”
2017-01-02 · Decoder with Nilay Patel · Recode Decode: Othman Laraki, CEO, Color · IDENTIFIED FROM THE TRANSCRIPT
“You know, that's the data point. But, you know, there's all this kind of low volume data, but that is carrying as much signal. Yeah, that's completely not being used. Like one example”
2017-01-02 · Decoder with Nilay Patel · Recode Decode: Othman Laraki, CEO, Color · IDENTIFIED FROM THE TRANSCRIPT
“So, what we do there is like, for example, we contribute aggregate data to a number of databases, for example, that are used to classify variants in terms of their impact on cancer and things like that. So these things really matter. And for example, a color customer by allowing us to do that can save the life of someone, you know. In France, who happens to have the same mutation that can now be classified. And so that really has, I think, a huge impact. I think the other piece, too, though, is just being able to use, I think there's a lot of right now the way data is used in medicine, I think, is we only use the super salient signals. Like, you know, you come in with a bleeding wound.”
2017-01-02 · Decoder with Nilay Patel · Recode Decode: Othman Laraki, CEO, Color · IDENTIFIED FROM THE TRANSCRIPT
“That if you have Yeah, and we found actually with color, everyone who takes a test. What happens to it? So they have the option to enable their anonymous data to be used for research.”
2017-01-02 · Decoder with Nilay Patel · Recode Decode: Othman Laraki, CEO, Color · IDENTIFIED FROM THE TRANSCRIPT
“Yeah, like privacy is taken as an excuse to kind of log data up. But ultimately, we own our health data and we need to be able to for it to be used for.”
2017-01-02 · Decoder with Nilay Patel · Recode Decode: Othman Laraki, CEO, Color · IDENTIFIED FROM THE TRANSCRIPT
“Yeah, so I think there is, like, it's almost like there are two separate problems. One is kind of how information is accessed and propagated. I think sometimes in healthcare,”
2017-01-02 · Decoder with Nilay Patel · Recode Decode: Othman Laraki, CEO, Color · IDENTIFIED FROM THE TRANSCRIPT